Moderna, Merck vaccine combo cuts skin cancer recurrence, death by 44 per cent

Philippines News News

Moderna, Merck vaccine combo cuts skin cancer recurrence, death by 44 per cent
Philippines Latest News,Philippines Headlines
  • 📰 nationalpost
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 80%

\u0027It\u0027s a tremendous step forward in immunotherapy\u0027

Paul Burton, Moderna’s chief medical officer, said in a separate interview the combination “has the capacity to be a new paradigm in the treatment of cancer.”

The Merck/Moderna collaboration is one of several combining powerful drugs that unleash the immune system to target cancers with mRNA vaccine technology. These so-called neoadjuvant vaccines are designed to target highly mutated tumours. When injected into a patient, the patient’s cells act as a manufacturing plant, producing perfect copies of the mutations for the immune system to recognize and destroy.

Moderna mRNA competitor BioNTech SE likewise has several cancer vaccine trials in the works including one with Memorial Sloan Kettering Cancer Center in New York, which is testing a personalized BioNTech vaccine in combination with Roche’s Tecentriq in patients with pancreatic cancer.Article content

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

nationalpost /  🏆 10. in CA

Philippines Latest News, Philippines Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Moderna, Merck vaccine combo cuts skin cancer recurrence, death by 44 per centModerna, Merck vaccine combo cuts skin cancer recurrence, death by 44 per cent\u0027It\u0027s a tremendous step forward in immunotherapy\u0027
Read more »

Moderna mRNA melanoma vaccine succeeds in combination with Merck drug - BNN BloombergModerna mRNA melanoma vaccine succeeds in combination with Merck drug - BNN BloombergModerna experimental personalized cancer vaccine reduced the risk of relapse or death from melanoma when combined with Merck Keytruda in a mid-stage trial, a key step in expanding the use of messenger RNA technology beyond COVID-19 prevention.
Read more »

Merck, Moderna detail potential skin cancer vaccine progressMerck, Moderna detail potential skin cancer vaccine progressShares of Merck and Moderna jumped early Tuesday after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots did well in a mid-stage study.
Read more »

Moderna, Merck vaccine combo cuts skin cancer recurrence, death by 44 per centModerna, Merck vaccine combo cuts skin cancer recurrence, death by 44 per cent\u0027It\u0027s a tremendous step forward in immunotherapy\u0027
Read more »

Merck, Moderna detail potential skin cancer vaccine progressMerck, Moderna detail potential skin cancer vaccine progressShares of Merck and Moderna jumped early Tuesday after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots did well in a mid-stage study.
Read more »

Experimental skin cancer vaccine shows promising early resultsExperimental skin cancer vaccine shows promising early resultsAn experimental cancer vaccine, combined with another drug, performed well in mid\u002Dstage testing against a deadly form of skin cancer.
Read more »



Render Time: 2025-03-04 20:57:40